BACKGROUND: Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa).
No such tables are available for locally advanced (cT3a) PCa.
OBJECTIVE: To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice.
DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective cohort study including 759 consecutive patients with cT3a PCa treated with RP between 1987 and 2010.
INTERVENTION: Retropubic RP and pelvic lymphadenectomy.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were divided into pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (GS) subgroups. These parameters were used to construct tables predicting pathologic outcome and the presence of positive lymph nodes (LNs) after RP for cT3a PCa using ordinal logistic regression.
RESULTS AND LIMITATIONS: In the model predicting pathologic outcome, the main effects of biopsy GS and pretreatment PSA were significant. A higher GS and/or higher PSA level was associated with a more unfavorable pathologic outcome. The validation procedure, using a repeated split-sample method, showed good predictive ability. Regression analysis also showed an increasing probability of positive LNs with increasing PSA levels and/or higher GS. Limitations of the study are the retrospective design and the long study period.
CONCLUSIONS: These novel tables predict pathologic stage after RP for patients with cT3a PCa based on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa.
PATIENT SUMMARY: Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.
Written by:
Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P. Are you the author?
Department of Urology, University Hospitals, Leuven, Belgium; Department of Urology, University of Bern, Bern, Switzerland; Department of Urology, San Raffaele Vita e Salute University, Milan, Italy; Department of Urology, Université Catholique de Louvain, Brussels, Belgium; Department of Urology, University Hospitals, Leuven, Belgium; Department of Urology, University of Piemonte Orientale, Novara, Italy; Department of Urology, University Medical Center Eppendorf, Hamburg, Germany; Department of Urology, Julius Maximilians Universität Würzburg, Würzburg, Germany; Department of Urology, Community Hospital Karlsruhe, Karlsruhe, Germany; Department of Urology, University of Turin, Turin, Italy; Department of Urology, Mayo Clinic, Rochester, MN, USA.
Reference: Eur Urol. 2014 Mar 21. pii: S0302-2838(14)00249-8.
doi: 10.1016/j.eururo.2014.03.013
PubMed Abstract
PMID: 24684960
UroToday.com Prostate Cancer Section
